Investment Analysts’ Weekly Ratings Updates for Agios Pharmaceuticals (AGIO)

A number of firms have modified their ratings and price targets on shares of Agios Pharmaceuticals (NASDAQ: AGIO) recently:

• 8/7/2026 – Agios Pharmaceuticals had its price target raised by JPMorgan Chase & Co. from $31.00 to $34.00. They now have a “neutral” rating on the stock.
• 7/31/2026 – Agios Pharmaceuticals had its price target raised by Citigroup Inc. from $46.00 to $52.00. They now have a “buy” rating on the stock.
• 7/31/2026 – Agios Pharmaceuticals had its price target lowered by Truist Financial Corporation from $41.00 to $39.00. They now have a “buy” rating on the stock.
• 7/30/2026 – Agios Pharmaceuticals had its price target raised by HC Wainwright from $52.00 to $55.00. They now have a “buy” rating on the stock.
• 7/21/2026 – Agios Pharmaceuticals had its price target lowered by HC Wainwright from $54.00 to $52.00. They now have a “buy” rating on the stock.
• 7/7/2026 – Agios Pharmaceuticals had its price target raised by Royal Bank Of Canada from $28.00 to $32.00. They now have a “sector perform” rating on the stock.
• 7/7/2026 – Agios Pharmaceuticals had its price target raised by Truist Financial Corporation from $36.00 to $41.00. They now have a “buy” rating on the stock.
• 7/7/2026 – Agios Pharmaceuticals had its price target raised by Bank of America Corporation from $40.00 to $46.00. They now have a “buy” rating on the stock.
• 6/24/2026 – Agios Pharmaceuticals had its “sell (d)” rating reaffirmed by Weiss Ratings.

Insider Transactions at Agios Pharmaceuticals

In related news, insider Sarah Gheuens sold 30,000 shares of Agios Pharmaceuticals stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $30.48, for a total transaction of $914,400.00. Following the sale, the insider directly owned 54,645 shares in the company, valued at $1,665,579.60. This trade represents a 35.44% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.40% of the stock is currently owned by company insiders.

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.